Localized
Localized
Advertisement
Michael D. Stifelman, MDLocalized | June 17, 2024
Drs. Stifelman and Ambinder discuss the novel approaches and adoption challenges of single-port and Da Vinci 5 systems.
View More
Neal Shore, MD, FACSLocalized | June 13, 2024
Dr. Shore discusses treatment-related adverse events associated with apalutamide and ADT.
Neal Shore, MD, FACSLocalized | June 13, 2024
Dr. Shore discusses the effects of apalutamide plus ADT in patients with prostate cancer.
Anthony M. Joshua, MBBS, PhD, FRACPLocalized | June 13, 2024
Drs. Joshua and Wallis contextualize the Metformin Active Surveillance Trial for management of low-risk prostate cancer.
Zachary BessetteProstate Cancer Diagnostics | June 11, 2024
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
Christopher Wallis, MD, PhD, FRCSCLocalized | June 3, 2024
The MAST trial evaluated metformin’s effects on reducing progression of low-risk prostate cancer during active ...
Zachary BessetteLocalized | May 31, 2024
Researchers attempted to confirm whether treatment suspension for EMBARK patients may lead to improvements in HRQOL.
Emily MenendezLocalized | May 10, 2024
Prostate cancer is the 2nd most diagnosed cancer among men worldwide, but the disease lacks established re-treatment options.
Katy MarshallLocalized | May 7, 2024
The trial evaluated the data of treatment-naïve patients who underwent RP and received apalutamide as well as ADT.
Zachary BessetteLocalized | May 6, 2024
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Katy MarshallLocalized | May 4, 2024
Investigators found that the NCHT cohort demonstrated increased 3-year bPFS benefits compared to the NHT cohort.
Daniel Spratt, MDLocalized | April 17, 2024
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
Emily MenendezProstate Cancer Diagnostics | April 10, 2024
Prostate-specific antigen density was the only clinical variable significantly associated with csPCa other than PI-RADS 5.
Steven Canfield, MDLocalized | April 9, 2024
Dr. Canfield shares real-world active surveillance among men with localized PC tested with the genomic prostate score assay.
Zachary BessetteLocalized | April 9, 2024
The 17-gene GPS assay can help physicians with clinical management plans for patients with localized PC.
Emily MenendezLocalized | April 8, 2024
cN1 patients with PCa who undergo initial treatment with RT have worse PCSM outcomes than those treated with RP.
Daniel Spratt, MDLocalized | April 5, 2024
Dr. Spratt reviews the safety and efficacy of relugolix plus RT in patients with localized or advanced prostate cancer.
James Sylora, MDLocalized | April 3, 2024
Dr. James Sylora shares his career, patient care, and vision for surgical and therapy advancements in community urology.
Emily MenendezLocalized | March 21, 2024
Relugolix was approved in 2020 for the treatment of localized prostate cancer based on the efficacy seen in the HERO trial.
Katy MarshallLocalized | March 18, 2024
Part 1 of the new guidelines covered treatment decision-making during suspected BCR following radical prostatectomy.
Advertisement
Advertisement
Advertisement